Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MannKind Corporation (MNKD : NSDQ)

• Company Description    Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder Technosphere formulation of insulin and the Company's MedTone inhaler through which the powder is inhaled into the deep lung. Number of Employees: 407

• Price / Volume Information    Yesterday's Closing Price: $3.60 Daily Weekly Monthly 20 Day Moving Average: 3,446,879 shares Shares Outstanding: 303.93 (millions) Market Capitalization: $1,094.16 (millions) Beta: 0.96 52 Week High: $7.63 52 Week Low: $3.52 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -16.28% -20.81% 12 Week -22.41% -34.91% Year To Date -44.01% -47.56%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1 CASPER STREET - DANBURY,CT 06810 USA ph: 818-661-5000 fax: 661-775-2081 ir@mannkindcorp.com http://www.mannkindcorp.com

• General Corporate Information    Officers Michael E. Castagna - Chief Executive Officer and Director Christopher B. Prentiss - Chief Financial Officer James S. Shannon - Chairman of the Board of Directors Steven B. Binder - Director Ronald J. Consiglio - Director Peer Information MannKind Corporation (CORR.) MannKind Corporation (RSPI) MannKind Corporation (CGXP) MannKind Corporation (BGEN) MannKind Corporation (GTBP) MannKind Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 56400P706 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/06/25 Share - Related Items Shares Outstanding: 303.93 Most Recent Split Date: 3.00 (0.20:1) Beta: 0.96 Market Capitalization: $1,094.16 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.04 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.18 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/25

• Fundamental Ratios P/E Current FY Estimate: 19.64 Trailing 12 Months: 22.50 PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: 25.94 Price / Sales: 3.68 EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: 33.33% Sales Growth vs. Year Ago Period: 18.25% vs. Previous Quarter: 2.06% ROE 06/30/25 - - 03/31/25 - -32.41 12/31/24 - -23.91 ROA 06/30/25 - - 03/31/25 - 10.85 12/31/24 - 9.98 Current Ratio 06/30/25 - - 03/31/25 - 2.36 12/31/24 - 3.28 Quick Ratio 06/30/25 - - 03/31/25 - 2.11 12/31/24 - 2.94 Operating Margin 06/30/25 - - 03/31/25 - 15.60 12/31/24 - 15.59 Net Margin 06/30/25 - - 03/31/25 - 10.12 12/31/24 - 9.66 Pre-Tax Margin 06/30/25 - - 03/31/25 - 11.17 12/31/24 - 10.69 Book Value 06/30/25 - - 03/31/25 - -0.19 12/31/24 - -0.29 Inventory Turnover 06/30/25 - - 03/31/25 - 2.79 12/31/24 - 2.90 Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©